Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus

Elliot S. Vesell, Charles E. Chambers, G. Thomas Passananti, Laurence M. Demers, Karl H. Beyer

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Pyrazinoylguanidine (PZG) reduced the hyperglycemia, hyperinsulinemia, and hyperlipidemia of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) as well as of normal subjects receiving hydrochlorothiazide (HCTZ). Mechanisms are proposed by which PZG downregulated the elevated glucose‐fatty acid cycle toward a more normal level in NIDDM patients and in non‐diabetic subjects maintained on HCTZ. Despite maintenance of these NIDDM patients on their current antihypertensive medication, PZG reduced further their systolic and diastolic pressures. PZG was well tolerated by both normal and NIDDM patients. 1993 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)823-831
Number of pages9
JournalThe Journal of Clinical Pharmacology
Volume33
Issue number9
DOIs
StatePublished - Sep 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effects of Pyrazinoylguanidine on the Glucose‐Fatty Acid Cycle in Normal Subjects and Patients with Non‐Insulin‐Dependent Diabetes Mellitus'. Together they form a unique fingerprint.

  • Cite this